title: Selective Sentinel Lymph Node Dissection in Lower Extremity Melanoma.
abstract: BACKGROUND
  There is debate as to whether deep inguinal lymph nodes should be removed with the superficial or femoral lymph nodes during sentinel lymph node biopsy for lower extremity melanoma, when both superficial and deep inguinal lymph nodes are identified by preoperative lymphoscintigraphy. This study evaluated the lymphatic drainage patterns in lower extremity melanoma to determine whether certain patterns could be used to limit the level of node removal and define the extent of dissection.
  
  
  METHODS
  A retrospective outcomes review was performed of lower extremity melanoma patients with excision and sentinel lymph node biopsy from 1995 to 2010. Outcomes included location of sentinel lymph node drainage basins, sentinel lymph node-positivity, and disease-free and overall survival, with drainage patterns compared between above- and below-knee melanomas.
  
  
  RESULTS
  Of 499 patients with lower extremity melanoma having sentinel lymph node biopsy, 356 had below-the-knee and 143 had above-the-knee melanoma. For below-knee melanoma, the node-positivity rate was 23 percent (63 of 271) for superficial inguinal, 0 percent (zero of three) for deep inguinal, and 50 percent (one of two) for popliteal basins. For above-knee melanoma, the positivity rate was 21 percent (24 of 113) for superficial inguinal, 33 percent (one of three) for deep inguinal basins, and 0 percent (zero of zero) for popliteal basins. Importantly, no patients with a negative superficial inguinal sentinel lymph node had a positive deep inguinal sentinel lymph node on final pathologic evaluation [corrected].
  
  
  CONCLUSIONS
  A difference was noted in patterns of sentinel lymph node drainage from lower extremity melanoma below and above the knee. Biopsy for deep inguinal basins may be deferred if there is simultaneous drainage to the superficial inguinal basin by preoperative lymphoscintigraphy.
  
  
  METHODS
  Risk, II.
authors.affiliation: San Francisco, Calif. From The Buncke Clinic, California Pacific Medical Center; the Departments of Surgery and Dermatology, University of California, San Francisco; Medivation Biostatistics; and the Center for Melanoma Research & Treatment, California Pacific Medical Center & Research Institute.
authors.forename: Suzette G
authors.initials: SG
authors.lastname: Miranda
authors.forename: Brian M
authors.initials: BM
authors.lastname: Parrett
authors.forename: Rui Rachel
authors.initials: RR
authors.lastname: Li
authors.forename: Grant
authors.initials: G
authors.lastname: Lee
authors.forename: Tiffany
authors.initials: T
authors.lastname: Chang
authors.forename: Niloofar
authors.initials: N
authors.lastname: Fadaki
authors.forename: Servando
authors.initials: S
authors.lastname: Cardona-Huerta
authors.forename: James E
authors.initials: JE
authors.lastname: Cleaver
authors.forename: Mohammed
authors.initials: M
authors.lastname: Kashani-Sabet
authors.forename: Stanley P
authors.initials: SP
authors.lastname: Leong
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D035002:Lower Extremity; D008197:Lymph Node Excision / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D012878:Skin Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D016019:Survival Analysis; D016896:Treatment Outcome
references.citation: Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
references.citation: Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol. 1993;2:303–308
references.citation: Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217–224
references.citation: Mariani G, Gipponi M, Moresco L, et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med. 2002;43:811–827
references.citation: Liu SH, Chang WC, Kao PF, et al. Lymphoscintigraphy and intraoperative gamma probe-directed sentinel lymph node mapping in patients with malignant melanoma. J Formos Med Assoc. 2004;103:41–46
references.citation: Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759–767
references.citation: Leong SP. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol. 2004;11(Suppl):192S–197S
references.citation: Stoffels I, Boy C, Pöppel T, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA. 2012;308:1007–1014
references.citation: Morton DL, Thompson JF, Cochran AJ, et al.MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
references.citation: Leong SP. Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma. Curr Treat Options Oncol. 2004;5:185–194
references.citation: Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012;29:699–706
references.citation: Strobbe LJ, Jonk A, Hart AA, Nieweg OE, Kroon BB. Positive iliac and obturator nodes in melanoma: Survival and prognostic factors. Ann Surg Oncol. 1999;6:255–262
references.citation: Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
references.citation: McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2002;9:137–141
references.citation: Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 2003;10:27–31
references.citation: Sabel MS, Gibbs JF, Cheney R, McKinley BP, Lee JS, Kraybill WG. Evolution of sentinel lymph node biopsy for melanoma at a National Cancer Institute-designated cancer center. Surgery. 2000;128:556–563
references.citation: Morton DL, Thompson JF, Cochran AJ, et al.MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
references.citation: Morton DL, Cochran AJ, Thompson JF. Authors’ response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg. 2007;245:828–829